What SEC filings does Exagen Inc. submit to the SEC?

Exagen Inc. (XGN) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about XGN?

A Form 4 for XGN discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Exagen Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for XGN?

The 10-K is Exagen Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all XGN SEC filings directly on EDGAR?

You can view all historical Exagen Inc. filings on the SEC EDGAR company page for XGN. Each filing card on this page links directly to the original SEC document.

How often does Exagen Inc. file with the SEC?

Exagen Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling XGN shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

XGN SEC Filing News — Exagen Inc.

Latest SEC filings for Exagen Inc. (XGN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-02.

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms in…

Sector: Healthcare Industry: Diagnostics & Research Market Cap: $180.0M CIK: 1274737

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for XGN currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

XGN Filing Activity Snapshot 2026-01-12 — 2026-09-02

Insider Transactions (Form 4)

0 buys vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$148.8K

Black Jeffrey G. (Chief Financial Officer) · 2026-09-02

20,614 shares · Form 4

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Exagen Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 7 compensation award and 4 open-market sale. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-09-02

XGN insider Black Jeffrey G. (Chief Financial Officer) sold 20,614 shares (~$148.8K)

Black Jeffrey G., listed as Chief Financial Officer at EXAGEN INC., reported an open-market sale of 20,614 XGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	20,614	$7.22	$148.8K
`A`	Compensation award	1,571	$3.02	$4.7K

Filing: Form 4 (Insider Transaction) Insider: Black Jeffrey G. (Chief Financial Officer) Shares: 20,614 Est. Value: $148.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-19

XGN insider Form 4 filed for equity award, exercise, or tax withholding

Robertson Bruce C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option(right to buy)	37,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Robertson Bruce C (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-19

XGN insider Form 4 filed for equity award, exercise, or tax withholding

Kim Paul (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option(right to buy)	37,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Kim Paul (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

XGN insider Form 4 filed for equity award, exercise, or tax withholding

KAHN SCOTT D (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option(right to buy)	37,500	—	—

Filing: Form 4 (Insider Transaction) Insider: KAHN SCOTT D (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

XGN insider Form 4 filed for equity award, exercise, or tax withholding

McKhann Chas (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option(right to buy)	37,500	—	—

Filing: Form 4 (Insider Transaction) Insider: McKhann Chas (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

XGN insider Form 4 filed for equity award, exercise, or tax withholding

Stokes Frank (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option(right to buy)	37,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Stokes Frank (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-16

XGN insider Form 4 filed for equity award, exercise, or tax withholding

Black Jeffrey G. (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	75,000	$3.16	$237.0K
`A`	Compensation award	1,511	$3.08	$4.6K
`A`	Compensation award derivative · Stock Option(right to buy)	50,000	$3.16	$158.0K

Filing: Form 4 (Insider Transaction) Insider: Black Jeffrey G. (Chief Financial Officer) Shares: 76,511

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-16

XGN insider Form 4 filed for equity award, exercise, or tax withholding

ABALLI JOHN (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	150,000	—	—
`A`	Compensation award derivative · Stock Option(right to buy)	100,000	$3.16	$316.0K

Filing: Form 4 (Insider Transaction) Insider: ABALLI JOHN (Director, President and CEO) Shares: 150,000

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-03-04

XGN insider ABALLI JOHN (Director, President and CEO) sold 15,698 shares (~$56.8K)

ABALLI JOHN, listed as Director, President and CEO at EXAGEN INC., reported an open-market sale of 15,698 XGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	15,698	$3.62	$56.8K
`A`	Compensation award	2,535	$3.08	$7.8K

Filing: Form 4 (Insider Transaction) Insider: ABALLI JOHN (Director, President and CEO) Shares: 15,698 Est. Value: $56.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-25

XGN insider ABALLI JOHN (Director, President and CEO) sold 11,430 shares (~$41.3K)

ABALLI JOHN, listed as Director, President and CEO at EXAGEN INC., reported an open-market sale of 11,430 XGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	11,430	$3.61	$41.3K

Filing: Form 4 (Insider Transaction) Insider: ABALLI JOHN (Director, President and CEO) Shares: 11,430 Est. Value: $41.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-25

XGN insider Black Jeffrey G. (Chief Financial Officer) sold 1,584 shares (~$5.7K)

Black Jeffrey G., listed as Chief Financial Officer at EXAGEN INC., reported an open-market sale of 1,584 XGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,584	$3.61	$5.7K

Filing: Form 4 (Insider Transaction) Insider: Black Jeffrey G. (Chief Financial Officer) Shares: 1,584 Est. Value: $5.7K

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for Exagen Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-04

XGN filed 8-K — material company event

EXAGEN INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-09

XGN filed 8-K — material company event

EXAGEN INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-11

XGN filed 8-K — material company event

EXAGEN INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-04-23

XGN filed 8-K — material company event

EXAGEN INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-03-10

XGN filed 8-K — material company event

EXAGEN INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-01-12

XGN filed 8-K — material company event

EXAGEN INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for Exagen Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-04

XGN filed Quarterly Report (10-Q)

EXAGEN INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-11

XGN filed Quarterly Report (10-Q)

EXAGEN INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-K Annual Report 2026-03-10

XGN filed Annual Report (10-K)

EXAGEN INC. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

View on SEC EDGAR → Open Filing Document →

How we classify Exagen Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on XGN. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — XGN SEC Filings

More Tools for XGN

XGN Full Stock Analysis XGN Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper XGN analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the XGN stock analysis page.

XGN Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer